New research indicates that patients using GLP-1 drugs for weight loss or diabetes management face a higher risk of developing alopecia compared to those taking other classes of diabetes medications. While the overall incidence remains low—estimated between 3 and 9 per 1,000 people annually—studies published in The BMJ and the Journal of the American Academy … Read more
Public health authorities are currently scrambling to secure medical countermeasures for an outbreak of the Bundibugyo strain of the Ebola virus in the Democratic Republic of Congo. With 2,473 confirmed cases and 999 deaths reported by the government, the lack of approved vaccines or treatments for this specific strain—which carries a fatality rate of up … Read more
Brazil’s Strategic Response to U.S. Tariffs Includes Patent Suspensions and WTO Revival Brazil is preparing to retaliate against U.S. tariffs by targeting intellectual property rights and audiovisual sector interests, according to three sources familiar with the discussions. The measures, which could include suspending pharmaceutical and agricultural seed patents, aim to pressure Washington while avoiding consumer … Read more
Global childhood vaccination rates rose slightly in 2025, with 90% of infants receiving at least one dose of the DTP vaccine, according to data from the World Health Organization (WHO) and UNICEF. Despite this, 13.5 million children remain “zero-dose,” leaving millions vulnerable to preventable diseases amid funding cuts and active conflicts. The Gap Between First … Read more
The U.S. Food and Drug Administration (FDA) has proposed a new regulatory framework designed to modernize how distributed pharmaceutical manufacturing sites register with the agency. Under the proposal, companies utilizing a “hub-and-spoke” manufacturing model—where a central location oversees multiple production units—would be permitted to register as a single establishment. The rule also mandates tighter reporting … Read more
The U.S. Food and Drug Administration (FDA) has officially accepted for review Sandoz’s applications for two generic versions of tirzepatide, the active ingredient in Eli Lilly’s popular weight-loss and diabetes treatments. This regulatory step marks a significant move toward potential market competition for Mounjaro and Zepbound ahead of the expiration of Eli Lilly’s U.S. patents … Read more
Roche has launched its Axelios gene sequencer, a new platform designed to perform large-scale DNA and RNA analysis, marking the company’s attempt to compete with industry leader Illumina. Roche aims to sell about 100 machines within the first year, targeting academic and research institutions to build a foundation for long-term growth in the $7.3 billion … Read more
Merck KGaA has announced an $11.3 billion agreement to acquire U.S.-based Bio-Techne, marking the German pharmaceutical giant’s largest acquisition since 2014. The deal, which offers $73 per share—a 24% premium over the closing price on Wednesday—is designed to bolster Merck’s life sciences division by integrating Bio-Techne’s extensive portfolio of research reagents, proteins, and analytical instruments … Read more
The U.S. government has begun shipping stockpiled doses of an experimental antibody drug, MBP134, from Mapp Biopharmaceutical to the Democratic Republic of Congo to combat a widening Bundibugyo Ebola outbreak. According to the U.S. Department of Health and Human Services, this shift in policy marks the first time Washington has released the treatment for clinical … Read more
From Terminal to Chronic: The New Era of Precision Oncology For decades, a cancer diagnosis often felt like a binary outcome. Today, that narrative is shifting. Thanks to a deeper understanding of the human genome, we are entering an era where cancer is increasingly managed as a chronic, long-term condition rather than an immediate death … Read more